Fulgent Genetics, Inc. (FLGT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$18.66-5.18%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · FLGT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -66.2% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 15.5% |
Growth built into the price is above our model estimate.
The price assumes 81.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 13 industry peers · Company calendar date is not available
FLGT — earnings miss
Dated 2026-11-05
Results of Operations and Financial Condition. On November 5, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Why it matters: The Phase 2 results showed tumor responses, but a larger trial must test if those results hold. A clear trial plan would mark progress.
Watch forFulgent names a start date, patient count, or trial sites for the planned Phase 3 study.
Also watch forFulgent reports that the Phase 3 study is delayed, paused, or no longer planned.
Why it matters: Fulgent plans about $610 million in year-end cash, assuming no more share repurchases and set spending. More spending could lower that figure.
Worry ifFulgent reports year-end cash below $610 million, buys back more shares, or spends above its stated plans.
Less concerning ifFulgent reports year-end cash near or above $610 million and no further share repurchases beyond the stated plan.
Why it matters: Management said both cancer drug trials are progressing. Trial delays or new safety problems could slow the pipeline.
Watch forThe November 5 update gives a trial milestone for FID-007 or FID-022, with no new pause or major safety issue.
Also watch forFulgent reports a trial pause, a missed stated milestone, or a new major safety issue for either drug.
Why it matters: Fulgent has completed the Bako Pathology deal, but the inputs show no clear revenue gain yet. Q3 results can show if the added business is contributing.
Watch forQ3 results name Bako revenue or show higher lab revenue. Fulgent also reports progress on integration.
Also watch forQ3 results cite Bako costs or delays. They name no revenue contribution or progress on integration.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$137 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $423 loss on $10,000 · 4.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,530 loss on $10,000 · 55.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.